quetiapine fumarate + SSRI/Clomipramine

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Obsessive Compulsive Disorder

Conditions

Obsessive Compulsive Disorder

Trial Timeline

Apr 1, 2002 → Mar 1, 2006

NCT ID

NCT00254735

About quetiapine fumarate + SSRI/Clomipramine

quetiapine fumarate + SSRI/Clomipramine is a phase 3 stage product being developed by AstraZeneca for Obsessive Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00254735. Target conditions include Obsessive Compulsive Disorder.

What happened to similar drugs?

5 of 9 similar drugs in Obsessive Compulsive Disorder were approved

Approved (5) Terminated (1) Active (3)

✅DuloxetineEli LillyApproved

🔄Fluvoxamine maleate + PlaceboAbbViePhase 3

✅Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)NovartisApproved

✅pregabalin + PlaceboPfizerApproved

✅EscitalopramLundbeckApproved

✅Escitalopram + Placebo oral tabletLundbeckApproved

🔄Troriluzole + PlaceboBiohavenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00254735	Phase 3	Completed	Apr 1, 2002	Mar 1, 2006	Obsessive Compulsive Disorder

Competing Products

17 competing products in Obsessive Compulsive Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine	Eli Lilly	Approved	43
Fluvoxamine maleate + Placebo	AbbVie	Phase 3	40
Quetiapine	AstraZeneca	Phase 2	35
Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)	Novartis	Approved	43
Bitopertin + Placebo + SSRI	Roche	Phase 2	35
sertraline	Pfizer	Pre-clinical	26
pregabalin + Placebo	Pfizer	Approved	43
Sertraline + Levetiracetam + Placebo	UCB	Phase 2/3	30
Escitalopram	Lundbeck	Approved	36
Escitalopram + Placebo oral tablet	Lundbeck	Approved	44
Valbenazine + Placebo	Neurocrine Biosciences	Phase 2	39
RG1068 (Synthetic Human Secretin)	Repligen	Phase 2	32
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 2/3	32
Troriluzole (BHV-4157)	Biohaven	Phase 3	26
Nitrous Oxide + Nitrogen	Brain Biotech	Phase 2	32